Global During the COVID-19 pandemic discussions around increasing access to medicines for low and middle-income countries (LMICs) were often centred on compulsory licensing. As a result, pharma companies were up in arms about protecting the intellectual property (IP) of their innovative medicines. But there is an alternative, says Charles Gore from…
Global The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this year’s edition that the 20 companies surveyed have firmly responded to access issues exposed by COVID-19. GSK remains at the…
See our Cookie Privacy Policy Here